The PD-1 Resistant Head and Neck Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the PD-1 Resistant Head and Neck Cancer market dynamics.
DelveInsight’s “PD-1 Resistant Head and Neck Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of Psoriatic Arthritis, historical and forecasted epidemiology as well as the PD-1 Resistant Head and Neck Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Key highlights of the PD-1 Resistant Head and Neck Cancer Market Report
- The global incidence of all Metastatic Head and Neck Cancers to be between 400,000 and 600,000 new cases per year and the mortality rate is between 223,000 and 300,000 deaths per year.
- Anti-PD-1 single agent response rates are only <20% in head and neck squamous cell carcinoma (HNSCC) patients, it is important to understand how multiple inhibitory checkpoint receptors maintain suppressed cellular immunity.
- Head and Neck Cancer is more common in men than in women.
- PD-1 Resistant Head and Neck Cancer market companies are included like TyrNovo Ltd. /Purple Biotech Ltd., AstraZeneca/Astex Pharmaceuticals, Inc., Adlai Nortye Biopharma, Astellas Pharma/Seattle Genetics, Rakuten Medical, Boehringer Ingelheim, Alkermes, and many others.
- PD-1 Resistant Head and Neck Cancer therapies are included like Keytruda (MK-3475), NBTXR3, and many others.
Download Sample Report- https://www.delveinsight.com/sample-request/pd-1-resistant-head-and-neck-cancer-hnc-market
Key benefits of the PD-1 Resistant Head and Neck Cancer Market report:
- PD-1 Resistant Head and Neck Cancer market report covers a descriptive overview and comprehensive insight of the Alcohol Use Disorder Epidemiology and PD-1 Resistant Head and Neck Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The PD-1 Resistant Head and Neck Cancer market report provides insights on the current and emerging therapies.
- PD-1 Resistant Head and Neck Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The PD-1 Resistant Head and Neck Cancer market report offers an edge that will help develop business strategies by understanding trends shaping and driving the PD-1 Resistant Head and Neck Cancer market
PD-1 Resistant Head and Neck Cancer Overview
Head and Neck Cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). These squamous cell cancers are often referred to as squamous cell carcinoma of Head and Neck Cancer. The symptoms of Head and Neck Cancers may include a lump or a sore that does not heal, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. Symptoms may vary depending upon the site of cancer.
PD-1 Resistant Head and Neck Cancer Symptoms
The symptoms of Head and Neck Cancers may include a lump or a sore that does not heal, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. Symptoms may vary depending upon the site of cancer.
PD-1 Resistant Head and Neck Cancer Treatment
For those able to receive treatment for metastatic spread, treatment again consists mainly of systemic therapies: cytotoxic chemotherapy, cytotoxic chemotherapy combined with cetuximab, or immunotherapy. For those who have a significant burden of symptoms but are still able to receive systemic therapy, single agent rather than combination therapy is recommended.
PD-1 Resistant Head and Neck Cancer Emerging Drugs
Monalizumab (IPH2201): AstraZeneca/Innate Pharma
Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T-cells and NK cells. NKG2A is an inhibitory checkpoint receptor for HLA-E. By expressing HLA-E, cancer cells can protect themselves from killing by NKG2A+ immune cells. HLA-E is frequently overexpressed on cancer cells of many solid tumors and hematological malignancies.
Buparlisib: Adlai Nortye Biopharma
Buparlisib is an oral pan-PI3K inhibitor that targets all class I PI3K isoforms and is active in both hematologic malignancies and solid tumors. Buparlisib significantly inhibited tumor growth in the animal model and showed a dose-response trend in anti-PD-1 refractory tumor-bearing mice. The dose range of buparlisib was consistent with previous preclinical studies conducted with BKM120 (Buparlisib, AN2025) by Novartis.
PD-1 Resistant Head and Neck Cancer Market Companies
- TyrNovo Ltd./ Purple Biotech Ltd.
- AstraZeneca/Astex Pharmaceuticals, Inc.
- AstraZeneca/Innate Pharma
- Adlai Nortye Biopharma
- Astellas Pharma/Seattle Genetics
- Rakuten Medical
- Boehringer Ingelheim
- Alkermes
- Seagen Inc. / Genmab
- Immutep S.A./Merck Sharp & Dohme Corp.
- Vyriad, Inc.
- Immunomedics, Inc.
- Seagen Inc.
- AstraZeneca
- Kymab Limited
- Bayer
- GlaxoSmithKline/MedImmune LLC
- Mereo BioPharma
- Debiopharm International SA
- Nektar Therapeutics
- Aadi Bioscience
- Bristol-Myers Squibb
- Merck Sharp & Dohme Corp. and Eisai
- Clinigen
- Pfizer
- Codiak BioSciences
- Ocellaris Pharma
- Genentech
- And many others
PD-1 Resistant Head and Neck Cancer Therapies
- Keytruda (MK-3475)
- NBTXR3
- And many others
Request Sample Report- https://www.delveinsight.com/sample-request/pd-1-resistant-head-and-neck-cancer-hnc-market
Table of Content
1. Key Insights
2. Executive Summary of PD-1 Resistant Head and Neck Cancer
3. Competitive Intelligence Analysis for PD-1 Resistant Head and Neck Cancer
4. PD-1 Resistant Head and Neck Cancer Market Overview at a Glance
5. PD-1 Resistant Head and Neck Cancer Disease Background and Overview
6. Patient Journey
7. PD-1 Resistant Head and Neck Cancer Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. PD-1 Resistant Head and Neck Cancer Unmet Needs
10. Key Endpoints of PD-1 Resistant Head and Neck Cancer Treatment
11. PD-1 Resistant Head and Neck Cancer Marketed Products
12. PD-1 Resistant Head and Neck Cancer Emerging Therapies
13. PD-1 Resistant Head and Neck Cancer (AUD): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: PD-1 Resistant Head and Neck Cancer Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. PD-1 Resistant Head and Neck Cancer Market Drivers
19. PD-1 Resistant Head and Neck Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
PD-1 Resistant Head and Neck Cancer Market Report Highlights
- In the coming years, the PD-1 Resistant Head and Neck Cancer (AUD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence PD-1 Resistant Head and Neck Cancer (AUD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for PD-1 Resistant Head and Neck Cancer (AUD). The launch of emerging therapies will significantly impact the PD-1 Resistant Head and Neck Cancer (AUD) market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for PD-1 Resistant Head and Neck Cancer (AUD)
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Why should you buy this report?
- The report will help in developing business strategies by understanding trends shaping and driving the PD-1 Resistant Head and Neck Cancer market
- To understand the future market competition in the PD-1 Resistant Head and Neck Cancer market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for PD-1 Resistant Head and Neck Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for PD-1 Resistant Head and Neck Cancer market
- To understand the future market competition in the PD-1 Resistant Head and Neck Cancer market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/